This article contains information on off‐label uses of VNS Therapy. Please review VNS Therapy prescribing information that can be found at the following link: https://us.livanova.cyberonics.com/healthcare‐professionals/prescribing‐information
We are pleased to inform you that you may access the online version of the article entitled: Long‐term surveillance of SUDEP in drug‐resistant epilepsy patients treated with VNS Therapy by Ryvlin P, et al, published in Epilepsia in 2018 at:
https://onlinelibrary.wiley.com/doi/abs/10.1111/epi.14002
This article is available as an open access article and is free of charge. We hope you will find this information useful.
The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications.
This study was funded by LivaNovaPLC and includes authors with financial interest in the company. Please see article disclosures.
The guideline below is available online to provide further information and references on the safety of off‐label use of VNS Therapy. This article is available as an open access article and is free of charge.
Evidence‐based guideline update: Vagus nerve stimulation for the treatment of epilepsy George L. Morris, David Gloss, Jeffrey Buchhalter, Kenneth J. Mack, Katherine Nickels, Cynthia Harden Neurology Oct 2013, 81 (16) 1453‐1459.
http://n.neurology.org/content/81/16/1453.long
For questions related to off‐label use of VNS Therapy, please contact Clinical Affairs at 800‐332‐1375.